Drug Trial Radar · NCT06361446
Zonisamide Versus Propranolol in Migraine
Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
600
Planned (sponsor's estimate)
Start
Mar 29, 2024
Primary completion
Mar 30, 2025
Study completion Apr 20, 2025
Sponsor
- Lead sponsor
- Kafrelsheikh UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigators aim to compare the effect of zonisamide versus propranolol in migraine by assessing the absolute reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency
Conditions
- Migraine
Interventions
Zonisamide 50 MGDrug
The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
PropranololDrug
The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in migraine days per 28 daysTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kafr Elsheikh University Hospital
Kafr ash Shaykh, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.